Anthropic's Mythos AI Model Sparks Emergency Cybersecurity Meeting With Top U.S. Bank CEOs 
Pony.ai, Uber, and Verne Launch Europe's First Commercial Robotaxi Service in Zagreb 
Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal 
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts 
Pilots Fear Retaliation for Refusing Middle East Flights Amid Ongoing Conflict 
Ford Issues Major Recall on Over 422,000 Vehicles Due to Windshield Wiper Defect 
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
OpenAI Addresses Security Vulnerability in macOS App Certification Process 
SanDisk Joins Nasdaq-100, Replacing Atlassian on April 20 
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth 
Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes 
Tokyo Electric Power Attracts Major Investors Amid Billion-Dollar Restructuring Push 
TSMC Posts Strong Q1 2025 Revenue, Riding AI Chip Demand Wave 
Rio Tinto's California Boron Assets Attract Over a Dozen Bidders, Valued at Up to $2 Billion 
San Francisco Suspect Arrested After Molotov Cocktail Attack on OpenAI CEO Sam Altman's Home 
CLEVELAND, Nov. 03, 2016 -- Athersys, Inc. (NASDAQ:ATHX) announced today that Gil Van Bokkelen, Chairman and CEO, will present at the Stifel 2016 Healthcare Conference at the Lotte New York Palace Hotel in New York. The presentation is scheduled for Wednesday, November 16, 2016 at 3:45 pm ET in the Garrison conference room.
A live audio webcast will be available via the investor relations page of the Athersys website at www.athersys.com. A replay of the presentation will be archived on the Athersys website for those unable to listen live.
About Athersys
Athersys is an international biotechnology company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life. The Company is developing its MultiStem® cell therapy product, a patented, adult-derived "off-the-shelf" stem cell product, initially for disease indications in the cardiovascular, neurological, inflammatory and immune disease areas, and has several ongoing clinical trials evaluating this potential regenerative medicine product. Athersys has forged strategic partnerships and collaborations with leading pharmaceutical and biotechnology companies, as well as world-renowned research institutions to further develop its platform and products. More information is available at www.athersys.com.
ATHX-G
Contact: William (B.J.) Lehmann, J.D. President and Chief Operating Officer Tel: (216) 431-9900 [email protected]
